Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard E Chaisson

Showing results (221-230 of 241) with videos related to

Pageof 25
Sort By:
BMJ Global Health|May 24, 2025
An evaluation of a choice architecture-based intervention on prescribing of TB preventive treatment to people living with HIV in southern Africa (the CAT study): a cluster-randomised trialKate Shearer, Bareng A S Nonyane, Christiaan Mulder, et al.
Annals of Internal Medicine|August 23, 2021
Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized TrialGavin Churchyard, Vicky Cárdenas, Violet Chihota, et al.
Plos One|May 10, 2016
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary TuberculosisMarcus B Conde, Fernanda C Q Mello, Rafael Silva Duarte, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2018
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of TuberculosisNicole C Ammerman, Rosemary V Swanson, Elaine M Bautista, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for TuberculosisHuy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
Emerging Infectious Diseases|March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with DiabetesEkaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
American Journal of Respiratory and Critical Care Medicine|February 18, 2003
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosisHenry M Blumberg, William J Burman, Richard E Chaisson, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
Emerging Infectious Diseases|January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Pageof 25

Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
BMJ Global Health|May 24, 2025
An evaluation of a choice architecture-based intervention on prescribing of TB preventive treatment to people living with HIV in southern Africa (the CAT study): a cluster-randomised trialKate Shearer, Bareng A S Nonyane, Christiaan Mulder, et al.
Annals of Internal Medicine|August 23, 2021
Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized TrialGavin Churchyard, Vicky Cárdenas, Violet Chihota, et al.
Plos One|May 10, 2016
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary TuberculosisMarcus B Conde, Fernanda C Q Mello, Rafael Silva Duarte, et al.
Antimicrobial Agents and Chemotherapy|May 9, 2018
Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of TuberculosisNicole C Ammerman, Rosemary V Swanson, Elaine M Bautista, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for TuberculosisHuy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
Emerging Infectious Diseases|March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with DiabetesEkaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
American Journal of Respiratory and Critical Care Medicine|February 18, 2003
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosisHenry M Blumberg, William J Burman, Richard E Chaisson, et al.
American Journal of Respiratory and Critical Care Medicine|July 16, 2024
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical TrialAva Y Xu, Gustavo E Velásquez, Nan Zhang, et al.
Emerging Infectious Diseases|January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
Pageof 25